1 / 31

Targeting the Cell Cycle in Lymphoma Therapy Selina Chen- Kiang Weill Cornell Medical College

Targeting the Cell Cycle in Lymphoma Therapy Selina Chen- Kiang Weill Cornell Medical College. CDK Inhibitors. Non-Selective CDK4/CDK6 inhibitors Targeting multiple CDKs, some are transcription factors Flavopiridol CDK9 Daniciclib CDK7 Selective CDK4/CDK6 inhibitors

kiona-dotson
Download Presentation

Targeting the Cell Cycle in Lymphoma Therapy Selina Chen- Kiang Weill Cornell Medical College

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Targeting the Cell Cycle in Lymphoma Therapy Selina Chen-Kiang Weill Cornell Medical College

  2. CDK Inhibitors • Non-Selective CDK4/CDK6 inhibitors • Targeting multiple CDKs, some are transcription factors • Flavopiridol CDK9 • Daniciclib CDK7 • Selective CDK4/CDK6 inhibitors • PD 0332991 (palbociclib) • Lymphoma, Myeloma • Solid tumors-Breast Cancer (ER+/HER-) • –Breakthrough therapy, combination with letrozole, Phase 3 • LEE011 • Breast Cancer –combination with letrozole and BYL719, Phase 3 • Melanoma • LY2835219 • Non-Small Cell Lung Carcinoma • Breast Cancer

  3. p16 p15 p18 p19 Cyclin D + CDK4/6 mid-G1 checkpoint p21 p27 p57 Cyclin E + CDK2 pST-Rb E2F release The Cell Cycle Positive Negative Go M pS-Rb-E2F G1 G2 S CDK: Cyclin-Dependent Kinase p18INK4c (CDKN2C)

  4. Targeting CDK4/6 with PD 0332991 (palbociclib) • Selective CDK4/CDK6 inhibitor (IC50 11 nM) • Orally bioavailable pyridopyrimidine • Competing with ATP for binding to the kinase site of CDK4/CDK6 • Induces early G1 arrest • Reversible • Low in toxicity • Selectively and potently inhibits CDK4/6 phosphorylation of Rb in • primary human myeloma cells (IC50 60 nM ) • Inhibits tumor growth in the NOD-SCID human myeloma xenograft • models and the immune-competent mouse 5T models Fry et al., 2004, Mol Cancer Ther Baughn et al., 2006, Cancer Research Menu et al., 2008, Cancer Research

  5. Targeting CDK4/CDK6 in combination therapy CDK4/6 Inhibitor Partner agent (low dose, selective ) Weill-Cornell Mantle cell lymphomaPhase I single agent Multiple Myeloma Phase I/II PD-bortezomib-Dex Mantle cell lymphomaPhase I PD 0332991-bortezomib 2014 Mantle cell lymphoma Phase I PD 0332991-Ibrutinib Multiple myeloma Phase I PD 0332991-Lenalidomide-Dex

  6. Prolonged inhibition of CDK4/6 Prolonged early G1 arrest (pG1) Expression of only genes programmed for early G1 Sensitizing tumor cells to cytotoxic killing Prolonged early G1 arrest (pG1) Hypothesis Go Cyclin D + CDK4/6 PD 0332991 M pS-Rb G1 G2 S

  7. pG1 Hypothesis Go PD 0332991 Reversible Cyclin D + CDK4/6 M pS-Rb G1 G2 S Release of prolonged early G1 block Cell cycle synchronization incompleterestoration of scheduled gene expression Further sensitizing tumor cells to cytotoxic killing

  8. Targeting CDK4/CDK6 in Recurrent MCL • Single agent PD 0332991 Phase I study • Inhibition of CDK4/CDK6 by PD 0332991 leads to prolonged G1 arrest (pG1) and increased tumor-specific cell death in MCL (n=17) • PD 0332991 (125 mg/d orally 21 of 28 d) is generally well • tolerated with neutropenia, fatigue and diarrhea as most • common adverse events • 1 complete response, 2 partial response, 5 SD > 1 year • Leonard, et al Blood 2012

  9. Phase I study of PD 0332991 + bortezomib in patients with recurrent MCL Biopsy★★★ pG1 pG1-S Martin, Di Liberto, Leonard, et al, unpublished

  10. Phase I study of PD 0332991 + bortezomib in patients with recurrent MCL % change in tumor size (by patient) Martin, Leonard, unpublished

  11. Inhibition of CDK4/6 induces early G1 arrest in MCL cells of both responders and non-responders initially. Can we identify genes that differentiate sensitivity from resistance to targeting CDK4 in combination with bortezomib? M. Di Liberto, D. Chiron, C. Mason, P. Martin, J. Leonard, S. Ely, unpublished

  12. Prolonged inhibition of CDK4/6 Prolonged early G1 arrest (pG1) Expression of only genes programmed for early G1 Sensitizing tumor cells to cytotoxic killing Prolonged early G1 arrest (pG1) Hypothesis Go Cyclin D + CDK4/6 PD 0332991 M pS-Rb G1 G2 S

  13. Longitudinal Integrative analysis of whole exome-sequencing (WES) and whole transcriptome-sequencing (WTS) of serial biopsies, using cheek swab as a control.

  14. Integrative WES and WTS analysis Lymph node biopsy CD5+CD19+ isolation WES (50ng DNA) WTS (100-100ng RNA) Alternative splicing CNV SNVs mRNAabundance

  15. Only 1% of the genes that were repressed in (pG1, day 8)in clinically responding patients (R) were up-regulated in pG1 non-responding patients (NR). Candidate biomarkers for the PD 0332991-bortezomib therapy? • Differential regulated genes • Glucose homeostasis • Redox homeostasis • Cell migration Chiron, Di Liberto, Mason, Martin, et al, unpublished

  16. Targeting CDK4 in combination with bortezomib in MCL • At the optimal PD 0332991 concentration and reduced bortzomib • 1 CR, 1 PR, 2 near PR (43% reduction), 1 SD, 1 PD. • Inhibition of CDK4 induces early G1 arrest that controls • cell cycle gene expression in all MCL patients initially. • MCL cells express CDK4 but not CDK6, cyclin D1 but not D2 or D3 • CDK4 is a stable target- no mutation in CDK4 detected • A small number of genes are oppositely regulated in pG1 • (day 8 vs day 0) in responders vs non-responders – candidate • biomarkers for targeting CDK4 in combination with bortezomib. • Glucose homeostasis • Redox homeostasis • Cell migration

  17. pG1 reprogramming MCL cells for ibrutinib inhibition of Bruton Tyrosine Kinase (BTK) Ibrutinib is effective in MCL. However, relapse is frequent and associated with aggressive proliferation and poor prognosis

  18. Relapse-specific C481S mutation in BTK in MCL --Longitudinal integrative WES and WTS analysis Chiron, Di Liberto, Martin et al, Cancer Discovery, 2014

  19. Relapse-specific C481S mutation in BTK in MCL --Longitudinal integrative WES and WTS analysis BTK C481S mutation undetected before Ibrutinib relapse • At least two mechanisms of Ibrutinib relapse - • BTKC481S mutation is detected in durable ibrutinib response (>14 or 30 months, 2/2. • However, BTKC481S mutation is absent in transient ibrutinib response (< 5months) or primary resistance (6/6) Chiron, Di Liberto, Martin et al, Cancer Discovery, 2014

  20. BTK is inactivated by ibrutinib in MCL cells of both • sensitive and resistant patients in vivo • PI3K-AKT is activated in ibrutinib resistance BTK BTKC481S Sensitive Relapse Sensistive Resistant Chiron, Di Liberto, Martin et al, Cancer Discovery, 2014

  21. Induction of pG1 by CDK4 inhibition reprograms MCL cells for killing by ibrutinib via inhibition of BTK and AKT Chiron, Di Liberto, Martin et al, Cancer Discovery, 2014

  22. pG1 inhibits NF-kB activation in BCR signaling Chiron, Di Liberto, Martin et al, Cancer Discovery, 2014

  23. Overriding ibrutinib resistance by cell cycle reprogramming • Integrative WES/WTS identified a BTK481S mutation at relapse • from ibrutinib after a durable response in MCL • BTK481S mutation is absent in transient ibrutinib response or • primary resistance, suggesting addition mechanisms for resistance. • BTK and AKT are concurrently activated in ibrutinib resistance. • Ibrutinib inactivates BTK in MCL cells of resistant patients. • Enhanced proliferation of MCL cells at relapse • pG1 sensitizes resistant MCL cells to Ibrutinib killing via cooperative • inactivate BTK and AKT, and inactivation of NF-kB. Chiron, Di Liberto, Martin et al, Cancer Discovery, 2014

  24. pG1 reprogramming of MCL cells for PI3K inhibition regardless of C481S BTK mutation Chiron, Di Liberto, Martin et al, Cancer Discovery, 2014

  25. pG1 reprograms MCL cells for PI3K inhibitor killing PI3Kd inhibitor GS-1101 (idelalisib) D. Chiron, M. Di Liberto, et al, Cell Cycle, 2013

  26. Induction of pG1 sustains the inactivation of AKT by PI3Kd inhibitor in MCL cells D. Chiron, M. Di Liberto, et al, Cell Cycle, 2013

  27. pG1 reprogramming for PI3K inhibition eradicates ibrutinib-resistant lymphoma cells independent of BTK mutation Cell death Live cells Chiron, Di Liberto, Martin et al, Cancer Discovery, 2014

  28. pG1 reprogramming of MCL cells for PI3K inhibition independent of C481S BTK mutation in MCL

  29. Future Directions- • Mechanism of pG1 sensitization • Cancer metabolism • Mechanism-based combination therapy for MCL • Targeting CDK4 with PD 0332991(palbociclib) in • combination with ibrutinib • Targeting CDK4 in combination with PI3K inhibitor • Mechanism of resistance • Identification of biomarkers via longitudinal integrative • WES/WTS and targeted sequencing

  30. The Team Maurizio Di LibertoXiangaoHuang David ChironDavid Jayabalan Selina Chen-Kiang John Leonard Ruben Niesvizky Peter Martin Tomer Mark Adriana Rossi Lewis Cantley Scott Ely Chris Mason Steve Gross Olivier Elemento Tim McGraw Jihye Paik Jeff Sharman Patients NIH/NCI V Foundation Lymphoma Research Foundation Leukemia and Lymphoma Society Starr Cancer Consortium

More Related